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Epidermal activation of Erk MAPK is observed in human psoriatic lesions and in a mouse model of psoriasis in
which b1 integrins are expressed in the suprabasal epidermal layers. Constitutive activation of the upstream kinase
MEK1 causes hyperproliferation and perturbed differentiation of human keratinocytes in culture. It is not known,
however, whether Erk activation in differentiating keratinocytes is sufﬁcient to trigger hyperproliferation of basal
keratinocytes and a skin inﬂammatory inﬁltrate. To investigate this, we expressed constitutively active MEK1 in the
suprabasal epidermal layers of transgenic mice. Proliferation in the epidermal basal layer was stimulated and
epidermal terminal differentiation was perturbed. Some older mice also developed papillomas. There was a large
increase in T lymphocytes, dendritic cells, and neutrophils in the skin. The effects of suprabasal MEK1 on basal
keratinocytes and leukocytes, cells that were transgene negative, suggested that MEK1 activity might stimulate
cytokine release. Transgenic keratinocytes expressed elevated IL-1a and crossing the mice with mice overex-
pressing the IL-1 receptor in the epidermal basal layer led to exacerbated hyperproliferation and inﬂammation.
These data suggest that activation of MEK1 downstream of b1 integrins plays an important role in epidermal
hyperproliferation and skin inﬂammation.
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b1 integrin extracellular matrix receptors regulate many as-
pects of epidermal cell behavior (Watt, 2002). In addition to
mediating keratinocyte adhesion and migration, they regu-
late the onset of terminal differentiation and couple differ-
entiation to movement from the basal into the suprabasal
epidermal layers. In human epidermis, stem cells express
high levels of b1 integrins and this protects them from in-
itiating terminal differentiation (Jones et al, 1995; Zhu et al,
1999; Watt, 2002; Evans et al, 2003).
Integrin expression is normally confined to the basal lay-
er of the epidermis. However, when the epidermis is hyper-
proliferative, for example during wound healing or in
psoriatic lesions, the receptors are also expressed in the
suprabasal layers (Watt and Hertle, 1994). Suprabasal inte-
grin expression is, in addition, a common feature of
squamous cell carcinomas. The functional significance of
suprabasal integrin expression has been examined by cre-
ating transgenic mice in which human integrin subunits are
expressed under the control of the involucrin promoter
(Carroll et al, 1995; Romero et al, 1999; Owens et al, 2003).
Transgenic mice expressing suprabasal a2b1, a3b1 or a5b1
can develop sporadic hyperproliferative lesions with an in-
flammatory infiltrate. The mice do not develop tumors
spontaneously, but show increased sensitivity to the
phorbol ester TPA; in addition suprabasal integrin expres-
sion can influence the number of tumors that develop during
chemical carcinogenesis (Owens and Watt, 2001; Owens
et al, 2003).
Activation of Erk MAPK is a key mediator of the effects of
b1 integrins in the epidermis. High b1 integrin expression by
epidermal stem cells in culture results in elevated activation
of Erk and introduction of a dominant negative mutant of the
upstream enzyme, MEK1, stimulates exit from the stem cell
compartment (Zhu et al, 1999). A tumor-associated b1
integrin mutation that results in increased keratinocyte
adhesion and impaired terminal differentiation also results
in sustained Erk MAPK activity (Evans et al, 2003). Supra-
basal integrins can activate Erk and in psoriatic lesions of
human and transgenic mouse there is activation of Erk in
the suprabasal, integrin-positive layers (Haase et al, 2001).
Constitutive activation of Erk MAPK by retroviral transduct-
ion of cultured human keratinocytes with mutant MEK1 re-
sults in hyperproliferation and perturbed differentiation,
recreating many of the histological features of psoriasis
(Haase et al, 2001).
There is some evidence that integrin-mediated activation
of Erk MAPK could contribute not only to epidermal hyper-
proliferation and perturbed differentiation, but also to the
inflammation that is a prominent feature of the lesions in
human psoriasis and integrin transgenic mice. Keratin-
ocytes cultured from the integrin transgenic mice produce
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more IL-1a than wild-type controls, independent of integrin
ligation (Haase et al, 2001; Hobbs and Watt, 2003). IL-1a
production by keratinocytes induces a dermal mononuclear
infiltrate (Groves et al, 1995), suggesting that IL-1 might
provide a link between suprabasal integrin expression and
skin inflammation (Haase et al, 2001; Hobbs and Watt,
2003). IL-1 activates Erk and Erk activation in turn increases
production of IL-1a (Haase et al, 2001; Hobbs and Watt,
2003). Expression of suprabasal b1 integrins can lead to
activation of Erk and IL-1a production by potentiating trans-
activation of the EGF receptor (EGFR) (Hobbs and Watt,
2003).
We have investigated whether activation of Erk ex-
clusively in the suprabasal epidermal layers is sufficient
to induce both epidermal hyperproliferation and skin
inflammation. The involucrin promoter was used to drive
expression of a constitutively active MEK1 construct in the
suprabasal epidermal layers of transgenic mice (InvEE
mice). Whereas the phenotype of the integrin transgenics
is sporadic (Carroll et al, 1995), the hyperproliferation and
skin inflammation of InvEE mice is constitutive. We present
evidence that the inflammation is due, at least in part, to
release of IL-1.
Results
Expression of an activated MEK1 construct in the sup-
rabasal layers of mouse epidermis produces hyperpro-
liferative and inﬂammatory skin lesions To produce a
sustained activation of Erk MAPK in the suprabasal layers of
mouse epidermis, expression of a constitutively activated
MEK1 construct, with two phospho-mimetic point muta-
tions (S217E/S221E) (Alessi et al, 1994; Cowley et al, 1994;
Zhu et al, 1999; Haase et al, 2001), was driven from the
involucrin promoter (Carroll et al, 1993, 1995). The trans-
genic mice in which the involucrin promoter is linked to the
activated MEK1 construct are referred to as ‘‘InvEE’’ mice.
The transgene cassette is shown in Fig 1. Three founder
lines were examined in detail: 3062A, 3376A, and 3359D.
Young animals did not have any gross phenotype, although
3376A animals were sometimes slightly runted. Older mice
from the 3376A line (and to a lesser extent the 3062A line)
often had ‘‘scruffy’’ coats and slightly flaky skin on all body
sites (data not shown).
To look for alterations in skin histology, samples were
collected from transgene-positive and -negative littermate
control mice of 2–3 mo age and sections stained with hem-
atoxylin and eosin (Fig 2A–F). Positive offspring from all
three founder lines (3062A, 3359D, and 3376A) showed
pronounced epidermal hyperproliferation and hyperkerato-
sis when compared to negative littermate controls. Further-
more, these mice had increased numbers of cells present in
the underlying dermis, indicative of an inflammatory infil-
trate. The skin phenotype was observed in both male and
female InvEE mice to a similar extent. Parakeratosis was not
generally observed in the mice (although see Fig 2D). The
sebaceous glands of InvEE skin were often enlarged (e.g.
Fig 2F) compared to control skin (e.g., Fig 2C). Mice from
the 3376A founder line produced the most consistently se-
vere phenotype.
To confirm the hyperproliferative status of epidermis
from InvEE mice, sections of skin from 3376A mice were
immunostained for the proliferative marker Ki67, which la-
bels cells in late G1, S, G2, and M phases of the cell cycle
(Fig 2G, H). Animals were also injected 1 h prior to death
with BrdU to label cells in S-phase of the cell cycle (Fig 2I,
J). InvEE epidermis contained increased numbers of both
Ki67 and BrdU-positive keratinocytes compared to negative
controls. Almost all of the Ki67 and BrdU-positive cells were
in the basal layer of the epidermis, which is transgene neg-
ative, as opposed to the suprabasal layers, where expres-
sion of the transgene is directed.
Sections of epidermis were immunolabelled with an an-
tibody to MEK1 to confirm that the transgene was correctly
expressed. In wild-type epidermis, there was low expres-
sion of MEK1 in the basal and suprabasal layers (Fig 2K). In
InvEE epidermis, there was an accumulation of MEK1 pro-
tein in the suprabasal, differentiating cell layers (Fig 2L), in-
dicating that the transgene was correctly expressed.
Preincubation of the MEK1 antibody with a blocking pep-
tide abolished this signal, demonstrating specificity (data
not shown). The MEK1 staining was exclusively cytoplasmic
(Fig 2L), consistent with the fact that MEK1 contains a nu-
clear export signal and acts as a cytoplasmic anchor for
inactive Erk1/2 (Fukuda et al, 1997a, b; Adachi et al, 2000).
Interfollicular epidermis of InvEE mice expresses kera-
tins associated with hyperproliferation In human and
mouse hyperproliferative and inflammatory skin lesions ex-
pression of keratins is perturbed. Keratin 14 protein is nor-
mally detected only in the epidermal basal layer; however,
staining extends to the suprabasal layers in hyperprolifer-
ative epidermis, such as psoriatic lesions (Wongwaisaya-
wan et al, 1991; Haase and Hunzelmann, 2002). In wild-type
control epidermis keratin 14 staining was predominantly
basal, whereas in InvEE transgenic epidermis staining ex-
tended to all the suprabasal layers (Fig 3A, B).
Keratins 6 and 17 are normally confined to the hair fol-
licles; however, they are also expressed in hyperproliferative
interfollicular epidermis (Stoler et al, 1988; Heyden et al,
1994; Mils et al, 1994; Leigh et al, 1995; McGowan and
Coulombe, 1998). Sections of skin from InvEE transgenic
and negative control mice were immunostained for keratins
6 and 17 (Fig 3). In negative control epidermis, keratin 6 was
completely absent from interfollicular epidermis and could
only be found in hair follicles (Fig 3C). Keratin 6, however,
was expressed in the interfollicular epidermis of transgenics
(Fig 3DF). The number of keratin 6-positive cells and in-
tensity of staining correlated with the extent of hyperprolif-
Figure 1
Construction of the InvEE transgene. The hu-
man involucrin promoter including the involucrin
intron (Carroll et al, 1993) was used to drive ex-
pression of an activated MEK1 mutant. The vec-
tor included SV40 splice (SDSA) and poly(A) sites.
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eration: areas of epidermis with extensive hyperproliferation
showed intense keratin 6 staining throughout all layers (Fig
3D) whilst regions of epidermis with more limited hyperpro-
liferation had patchy keratin 6 expression (Fig 3E, F). In
transgene-negative epidermis, keratin 17 was only detected
in the hair follicles (data not shown) and was absent from
the interfollicular epidermis (Fig 3G). In contrast, the inter-
follicular epidermis of transgenic mice was positive for ker-
atin 17 (Fig 3H).
Expression of terminal differentiation markers is per-
turbed in InvEE epidermis To examine whether the ter-
minal differentiation program of keratinocytes in the
epidermis of InvEE transgenic mice was perturbed, sec-
tions of transgenic and negative control epidermis were
stained using antibodies to a variety of differentiation mark-
ers (Fig 4).
Keratin 10 expression was detected in all the suprabasal
layers of wild-type epidermis (Fig 4A). The onset of keratin
10 expression was delayed in InvEE epidermis, which con-
tained several suprabasal, keratin 10-negative layers (Fig
4B). Involucrin expression was confined to the most sup-
rabasal cells of wild-type epidermis (Fig 4C), whereas in
InvEE transgenic epidermis the onset of expression coin-
cided with the onset of keratin 10 expression (Fig 4D, cf. Fig
4B). The layers in which involucrin were expressed were
also the layers in which elevated MEK1 were detected (Fig
2L), confirming previous observations that the involucrin
promoter is active in those cells that express the endog-
enous protein (Carroll et al, 1993).
In human psoriatic lesions there is no granular layer and
nuclei are retained in the cornified layers (parakeratosis)
(Bernard et al, 1988). Sections of psoriatic skin show re-
duced or absent expression of the granular layer markers
loricrin and filaggrin (Watanabe et al, 1991; Juhlin et al,
1992; Hohl, 1993). InvEE epidermis was not generally
parakeratotic (Fig 2B, D, F) and expression of filaggrin
and loricrin was enhanced compared to controls, with sev-
eral suprabasal layers of InvEE epidermis staining positive
for these markers (Fig 4E–H). It thus seems that whilst early
stages of terminal differentiation are delayed in keratin-
ocytes of InvEE epidermis (i.e., keratin 10 expression), the
later stages are enhanced (more extensive loricrin and fi-
laggrin expression). The increased granular layer develop-
ment and lack of parakeratosis displayed by transgenic
epidermis demonstrates that while the epidermis is mas-
sively hyperproliferative, the terminal differentiation program
of the keratinocytes still runs to completion.
InvEE transgenics develop a mixed inﬂammatory in-
ﬁltrate As shown in Fig 2B, D, and F, InvEE transgenics
displayed a dermal infiltrate suggestive of a cutaneous
Figure 2
InvEE transgenic mice have hyperproliferative and inflammatory skin lesions. (A–F) Sections of H&E stained back skin from three independent
InvEE transgenic founder lines (B—3062A, D—3359D, F—3376A) and corresponding negative littermate controls (A, C, E). Paraffin-embedded
sections from InvEE transgenic (H, J, L) and negative controls (G, I, K) were stained for Ki67 (G, H), BrdU incorporation (I, J) and total MEK1 (K, L).
Dashed line in (I, J) represents the basement membrane and red nuclear counterstain in (K, L) is TOPRO. Scale bars¼ 100 mm (A–F) and 50 mm (G–L).
Sebaceous glands in (C) and (F) are labelled ‘‘SG’’.
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inflammatory response. To characterize the infiltrate, sec-
tions of skin from transgenic and negative control mice were
stained using antibodies to markers of a variety of immune
cells (Fig 5). Staining for the pan T cell marker CD3 revealed
a large increase in T cells in the dermis of InvEE transgenics
compared to controls and increased numbers of CD3-
positive cells in the transgenic epidermis (Fig 5A, B). The
extensive dermal T cell infiltrate in InvEE transgenics was
composed mainly of CD4-positive cells (Fig 5C, D), and a
limited number of CD8-positive T cells was detected in the
epidermis of severely affected transgenics (Fig 5E, F). The
increased numbers of CD3-positive cells in the epidermis
are thus likely to represent both resident gd T cells (Matsue
et al, 1993; Salerno and Dieli, 1998) and infiltrating T cells.
The InvEE lymphocyte infiltrate is thus similar to that de-
veloped in Invb1 integrin transgenic mice and in human
psoriatic lesions (Carroll et al, 1995).
Together with the extensive T cell infiltrate, InvEE
transgenics had a substantial F4/80-positive macrophage
infiltrate in the dermis and a small increase in epidermal F4/
80-positive cells (Fig 5G, H). There was also a slight in-
crease in the number of dendritic cells (DEC-205 positive) in
the epidermis (Fig 5I, J) and neutrophils were present in the
dermis of transgenic but not control skin (Fig 5K, L).
Taken together, these data demonstrate that constitutive
activation of Erk MAPK in the suprabasal layers of mouse
epidermis is sufficient to generate a cutaneous inflamma-
tory infiltrate composed chiefly of macrophages and CD4-
positive T cells. In InvEE skin epidermal hyperproliferation
was always accompanied by an inflammatory infiltrate.
InvEE transgenic keratinocytes express increased lev-
els of the pro-inﬂammatory cytokine IL-1a We have pre-
viously shown that suprabasal integrin expression results
in activation of Erk MAPK and increased IL-1a production
(Haase et al, 2001; Hobbs and Watt, 2003). To establish
whether IL-1a expression was increased in InvEE transgenic
epidermis and to examine the effect of the transgene on Erk
activation, primary keratinocytes were isolated from six in-
dividual neonatal mice of one litter from the 3376A founder
Figure 3
Keratin expression is altered in epidermis of InvEE mice. Acetone-
fixed frozen sections of InvEE transgenic (B, D, E, F, H) and negative
control (A, C, G) skin stained for keratins 14 (A, B), 6 (C–F) and 17 (G,
H). Scale bars¼100 mm (A, B, E–H) and 50 mm (C, D).
Figure4
Keratinocyte terminal differentiation is perturbed in InvEE trans-
genic epidermis. Paraffin embedded (A–D) and acetone-fixed frozen
(E–H) sections of epidermis were stained for keratin 10 (A, B), involucrin
(C, D), filaggrin (E, F) and loricrin (G, H). Transgene-negative control
epidermis is shown in (A, C, E, G) and InvEE transgenic epidermis in (B,
D, F, H). Blue nuclear counterstain in (A–D) is DAPI. The basal layer of
the epidermis is indicated with arrow heads in (B). Scale bar¼ 50 mm.
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line. Two of the mice (numbers 2 and 4 in Fig 6) were pos-
itive for the transgene. Second passage keratinocytes from
each of the six mice were incubated overnight in complete
low-calcium medium, or transferred to standard (‘‘high-cal-
cium’’) medium to induce stratification and accumulation of
terminally differentiating cells. Lysates were collected from
the keratinocytes and analyzed by western blotting (Fig 6).
The InvEE transgene includes a (His)6 tag (Fig 1) which
was detected as a band of approximately 45kDa in low- and
high-calcium cultures of cells from mice 2 and 4 (Fig 6),
confirming that the transgene continued to be expressed in
culture. Furthermore, under both experimental conditions
transgenic keratinocytes expressed higher levels of total
MEK1 than the negative controls. Cultured keratinocytes
from mouse 2 expressed higher levels of the transgene,
detected with either the anti-(His)6 tag or the anti-MEK1
antibody than those from mouse 4 (Fig 6).
There was no significant difference in levels of phospho-
Erk1/2 between transgene-positive and -negative cells cul-
tured in low-calcium medium and only a very minor, yet
detectable, difference in high-calcium medium (Fig 6). Lev-
els of phospho-Erk1/2 in both transgene-positive and wild-
type control cells decreased in high-calcium medium, an
effect consistent with the role of Erk in maintaining keratin-
ocyte proliferation and inhibiting terminal differentiation (Zhu
et al, 1999; Haase et al, 2001; Dajee et al, 2002; Tarutani
et al, 2003). We were unable to demonstrate increased
phopho-Erk1/2 consistently by immunostaining of InvEE
epidermis (data not shown). These results indicate that the
MEK1 transgene drives a very low level of Erk activation,
suggesting that keratinocytes are able to induce negative
feedback pathways to limit Erk activity (Brondello et al,
1997, 1999) and that the low level of continued stimulation
induced in transgenics must be sufficient to produce the
observable phenotype. The possibility that MEK1 is acti-
vating other downstream pathways more efficiently than Erk
in the keratinocytes is unlikely as Erk is considered its only
physiological substrate (Dhanasekaran and Premkumar
Reddy, 1998; Kolch, 2000).
Keratinocytes with the highest detectable expression of
the transgene (from mouse 2) expressed higher levels of
proIL-1a in low- and high-calcium medium than transgene-
negative controls (Fig 6). This was particularly noticeable
when cells were transferred to high-calcium medium, con-
ditions which normally inhibit IL-1a expression (Hobbs and
Watt, 2003). Keratinocytes from InvEE mouse 4, which ex-
pressed lower amounts of the MEK1 transgene than mouse
2 cells, did not have increased IL-1a levels, suggesting that
a threshold of transgene expression needs to be reached
before effects on IL-1a expression are observed. Levels of
the IL-1 receptor anatagonist icIL-1ra (Haskill et al, 1991;
Bigler et al, 1992) were not altered in InvEE-positive cells
(Fig 6).
To determine whether IL-1a levels were also increased
in vivo we performed RT-PCR (Fig 6B) and immunofluores-
cence microscopy (Fig 6C) on skin from InvEE mice and
wild-type littermate controls. The RT-PCR reactions were
examined every five cycles between 15 and 35 cycles in
order to obtain semi-quantitative comparisons. During the
linear phase of amplification (25 cycles) the level of IL-1a
Figure 5
Skin of InvEE transgenic mice has an inflammatory infiltrate. Acetone fixed frozen (A–J) and paraffin embedded (K, L) skin sections from InvEE
mice (B, D, F, H, J, L) and transgene-negative controls (A, C, E, G, I, K) were stained for the following markers to a variety of immune cells: CD3 (A, B),
CD4 (C, D), CD8 (E, F), F4/80 (G, H), DEC-205 (I, J) and for neutrophils (K, L). Scale bar¼ 50 mm (A–F) and (G–L). Sections (A–F) were counterstained
for keratin 14 in red to distinguish the epidermis.
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mRNA was at least 5-fold greater in InvEE skin than in
transgene-negative littermates, whereas there was no dif-
ference in the levels of IL-1b or GAPDH (Fig 6B). The
increased expression of IL1-a was confirmed by immuno-
fluorescence staining: IL-1a was readily detected in all
layers of the epidermis of transgenic mice but was not de-
tectable above background in littermate controls (Fig 6C).
We conclude that the MEK1 transgene was expressed in
InvEE keratinocytes and could increase IL-1a expression
both in vivo and in culture.
Increased IL-1a production by epidermal keratinocytes
of InvEE mice contributes to the hyperproliferative and
inﬂammatory phenotype Given the central role of kera-
tinocyte-derived IL-1a in triggering cutaneous inflammatory
responses (Kupper and Groves, 1995) and regulating ker-
atinocyte proliferation and differentiation (Maas-Szabowski
et al, 1999, 2000; Szabowski et al, 2000; Werner and Smola,
2001), we investigated whether increased IL-1a expression
contributed to the phenotype of InvEE mice. To do this, we
crossed InvEE mice with transgenic mice that overexpress
the type 1 IL-1R from the keratin 14 promoter (K14-IL-1R1
transgenics). K14-IL-1R1 transgenic mice have no sponta-
neous phenotype but show enhanced epidermal sensitivity
to IL-1 and amplify IL-1-dependent responses via increased
production of IL-1-inducible secondary cytokines such as
GM-CSF and gro-a (Groves et al, 1996). Since the InvEE
and K14-IL-1R1 mice were heterozygous for each trans-
gene crosses produced mice positive for both or one or
other of the transgenes as well as transgene-negative
mice.
Skin of mice that were positive for the K14-IL-1R1 trans-
gene alone showed no epidermal hyperproliferation or
spontaneous inflammation (Fig 7B) and was, therefore, in-
distinguishable from transgene-negative mouse skin (Fig
7A). Mice that were positive for the InvEE transgene alone
developed the hyperproliferative epidermis and accompa-
nying inflammatory infiltrate already described (Fig 7C; see
also Fig 2B, D, and F). Five of eight mice that were positive
for both the MEK1 and IL-1R1 transgenes displayed an
Figure 6
Keratinocytes from InvEE transgenic
mice have elevated IL1a expression in
culture and in vivo. (A): Primary mouse
keratinocytes (passage 2) were isolated
from the 6 individual neonates (numbered
1–6) of a litter containing InvEE transgenic
and wild-type mice (Founder line 3376A).
Confluent cultures from each mouse were
incubated overnight in low or high calcium
medium, lysed and analyzed by western
blotting for the proteins indicated. Mice
that were positive for the transgene are
indicated by . Loading controls are actin
and ERK2. (B): RT-PCR (cycle 25) of RNA
from InvEE and transgene-negative (WT)
littermate skin using primers to the
mRNAs shown. Cont: control lanes lack-
ing RNA. C: Immunofluorescence staining
of wild-type and InvEE epidermis with an-
ti-IL-1a. Position of the basement mem-
brane is indicated by dashed line. Scale
bar is 50 mm.
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exacerbated skin phenotype when compared to either lit-
termate or sex- and age-matched InvEE single transgenics
(Fig 7D).
The interfollicular epidermis of double transgenics was
thicker than InvEE epidermis, with focal increases both in
the number of viable cell layers and in the number of dead,
cornified layers (Fig 7D). The proliferative status of the ep-
idermal basal layer was measured by BrdU incorporation
using a recently developed whole mount labelling protocol
that allows large areas of interfollicular epidermis to be ex-
amined simultaneously in mouse tail skin (Braun et al, 2003;
Niemann et al, 2003). Whole mounts were double labelled
with antibodies to BrdU and keratin 14 (to visualize the ba-
sal layer of the interfollicular epidermis and the outer root
sheath of the hair follicles). The number of BrdU-positive
cells was increased in InvEE whole mounts (Fig 7G) com-
pared to wild-type (Fig 7E) and K14IL-1R1 transgenic (Fig
7F) epidermis. In the double transgenics, the number of
BrdU-labelled cells was increased even further (Fig 7H).
Labelling the whole mounts for DEC-205 allowed us to
visualize dendritic cells in the epidermis. The number of
dendritic cells was higher in InvEE epidermis (Fig 7K) than
in wild-type (Fig 7I) or K14-IL-1R1 (Fig 7J) epidermis. The
double transgenics had even more dendritic cells (Fig 7L)
than the single InvEE transgenics (Fig 7K).
We conclude that crossing InvEE transgenics with mice
that overexpress the type 1 IL-1 receptor enhances epider-
mal hyperproliferation and inflammation. Thus increased IL-
1 production in InvEE epidermis is likely to contribute to
their hyperproliferative and inflammatory phenotype.
InvEE transgenic mice develop hyperkeratotic and in-
ﬂammatory lesions on the feet and papillomas at sites of
skin injury As they grew older (typically from 3 mo), the
majority of InvEE mice from the 3376A founder line accu-
mulated large amounts of cornified material on their foot
pads (Fig 8A, B, cf. C). The nails tended to overgrow and
become twisted (Fig 8B) and in extreme cases the nails
became large horny masses that were poorly defined from
the digits themselves (Fig 8A).
In hematoxylin- and eosin-stained sections of wild-type
feet, the epidermis of the ventral surface was thicker than
that of the dorsal surface (Fig 8D). This distinction was not
as clear in InvEE transgenics, with both surfaces showing
abnormal epidermal thickening and accumulation of corni-
fied layers (Fig 8E). In transgenics, there was enlargement of
Figure 7
Mice positive for both the InvEE and K14-IL-1R1 transgenes have an exacerbated phenotype. Sections of back skin (A–D) or whole mounts of
tail skin (E–L) were stained with haematoxylin and eosin (H&E) (A–D), for BrdU incorporation (green in E–H) and for DEC-205 (red in I–L). Skin was
from age-matched males (4 mo old) that were either transgene-negative (wild-type: A, E, I), positive for the K14-IL-1R1 (B, F, J) or InvEE transgenes
(C, G, K) only or positive for both K14-IL-1R1 and InvEE transgenes (D, H, L). Red counterstain in (E–H) is keratin 14. The arrowheads in ( I ) indicate
DEC-205-positive dendritic cells within the interfollicular epidermis. Scale bar¼100 mm (A–D) or 160 mm (E–L). Note that many of the hair follicles in
the whole mounts (EL) have ruptured during preparation.
Erk MAPK AND INFLAMMATION 509123 : 3 SEPTEMBER 2004
the sweat glands (Fig 8G, asterisk) and a considerable der-
mal inflammatory infiltrate (Fig 8G) compared to controls
(Fig 8F). Transgenic epidermis was severely hyperprolifer-
ative and contained many more Ki67-positive cells (Fig 8I)
than controls (Fig 8H). Even though almost all of the basal
cells in InvEE epidermis were Ki67 positive, there were very
few suprabasal Ki67-positive cells (Fig 8I).
Between 2 and 4 mo of age, several male and female
InvEE mice from the 3376A line and one male mouse of the
3062A line developed papillomas at sites of wounding, such
as the tail, lower back and ears (Bailleul et al, 1990) (Fig 9A,
B) or on the soles of the feet. Ki67-positive cells were pre-
dominantly localized to the basal layer of the InvEE pap-
illomas (Fig 9C), indicating their benign nature (Glick et al,
1993; Brown et al, 1998) and no papillomas were observed
to convert to squamous cell carcinomas.
The InvEE papillomas from both 3376A and 3062A
founder lines expressed substantial quantities of involucrin
in the suprabasal layers (Fig 9D) and by staining serial sec-
tions with antibodies to MEK1 we established that there
was a large accumulation of MEK1 in the same cells (Fig
9E). Pre-incubation of the MEK1 antibody with blocking
peptide abolished the staining, demonstrating the specifi-
city of the antibody (Fig 9F). Papillomas induced in non-
transgenic mice by a standard DMBA initiation, TPA pro-
motion protocol (Owens and Watt, 2001) also contained
many involucrin-positive cells (Fig 9G), as previously de-
scribed (Li et al, 2000), but in this case the staining for MEK1
was weak and predominantly basal (Fig 9H). In InvEE pap-
illomas, strong expression of IL-1a was detected by
immunofluorescence staining, whereas IL-1b was not de-
tected in the epithelial compartment (Fig 9I and data not
shown).
Discussion
We have generated transgenic mice expressing activated
MEK1 in the suprabasal layers of the epidermis via the in-
volucrin promoter (InvEE mice). The epidermis of these mice
was hyperproliferative, with perturbed keratin expression
and changes in the terminal differentiation programme.
InvEE mice also developed an extensive inflammatory
infiltrate containing a variety of immune cells. The data
obtained from the InvEE mice suggest that the active Erk1/2
detected in suprabasal layers of human psoriatic lesions
(Haase et al, 2001) may contribute to the epidermal hyper-
proliferation and inflammatory infiltrate that are hallmarks of
the disease, and support the hypothesis that suprabasal
expression of b1 integrins triggers hyperproliferation and
inflammation (Carroll et al, 1995) through activation of Erk
MAPK (Haase et al, 2001). Whereas the phenotype of Invb1
transgenics is sporadic (Carroll et al, 1995; Romero et al,
1999) the hyperproliferation and inflammation of InvEE skin
is constitutive, consistent with the observation that supra-
basal integrin expression is not sufficient to activate Erk, but
rather sensitizes the cells to additional stimuli (Haase et al,
2001; Owens and Watt, 2001; Hobbs and Watt, 2003).
While the hyperproliferation, altered keratin expression
and inflammatory infiltrate of InvEE mice were all changes
seen in human psoriatic lesions, one obvious difference was
in the final stages of epidermal differentiation. Psoriatic
lesions tend to be parakeratotic, that is, the nuclei are
retained in the outermost cornified layers, and there is a
corresponding absence of the granular layer (Bernard et al,
1988). In contrast, parakeratosis was hardly ever seen in
InvEE epidermis and the granular layer was more extensive
than wild-type controls. Since parakeratosis was a feature
of the Invb1 lesions (Carroll et al, 1995) there must be ad-
ditional, Erk-independent, mechanisms by which supraba-
sal integrin expression leads to deregulation of the final
stages of epidermal differentiation.
The major effects of the InvEE transgene were exerted on
cells that did not express the transgene: the increased ep-
idermal proliferation was confined to the epidermal basal
layer and inflammatory cells accumulated in both epidermis
and dermis. This suggests that activation of MEK1 in sup-
Figure 8
The feet of InvEE transgenic mice have hyperproliferative and in-
flammatory lesions. Front (A) and rear (B) feet of a 3.5-mo-old InvEE
transgenic male (line 3376A). A negative control front foot is shown in
(C). Sections of severely affected InvEE transgenic (E, G, I) and trans-
gene-negative control (D, F, H) feet were stained with H&E (D–G) or
immunolabelled for Ki67 (H, I). Scale bars are 500 mm (D, E) and 100 mm
(F, G and H, I). The ventral foot surface (bottom of sections in D, E) is
shown in (F–I). Sweat glands are marked with  in (F, G).
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rabasal keratinocytes may stimulate production of diffusible
factors. Epidermal-derived cytokines are known to pene-
trate the underlying basement membrane and enter the
dermis (Kondo et al, 1997). We have established that one of
those factors is the potent pro-inflammatory cytokine IL-1a.
InvEE keratinocytes in vivo and in culture produced in-
creased levels of IL-1a provided that the transgene was
expressed at a sufficiently high level (Fig 6), consistent with
the observation that expression of IL-1a in wild-type and
Inva2b1 keratinocytes can be regulated by Erk MAPK (Hob-
bs and Watt, 2003). Furthermore, crossing InvEE mice with
mice overexpressing the IL-1R1 from the keratin 14 pro-
moter (which amplifies IL-1-dependent processes in the
epidermis) (Groves et al, 1996) exacerbated the InvEE skin
phenotype (Fig 7).
IL-1 has a well-studied role in epidermal biology: it can
regulate the proliferation and differentiation of keratinocytes
within the epidermis and also potently trigger cutaneous
inflammatory processes (Murphy et al, 2000; Freedberg
et al, 2001; Werner and Smola, 2001). While IL-1b is the
dominant form of IL-1 produced by haemopoietic cells and
is readily detected in the dermis, IL-1a is more abundant in
the epidermis (Murphy et al, 2000). IL-1a was upregulated in
InvEE epidermis and papillomas, whereas IL-1b was not
(Fig 6 and data not shown). In human psoriatic skin lesions
IL-1a levels are decreased while IL-1b is increased (see,
e.g., Cooper et al, 1990; Bonifati et al, 1997), but the inter-
pretation of these results is complicated by the need to
consider the levels of IL-1 receptors and receptor antago-
nists (Terui et al, 1998) and also the contributions of different
cell types within the skin. What is clear is that epidermal
overexpression of IL-1a can perturb epidermal homeostasis
and trigger cutaneous inflammation. Transgenic mice which
overexpress IL-1a in their epidermis from the keratin 14
promoter (K14-IL-1a mice) generate a macrophage/mon-
ocyte infiltrate with hyperkeratotic epidermis (Groves et al,
1995). The IL-1a mice also display spontaneous focal
inflammatory lesions containing a mixed inflammatory infil-
trate (including lymphocytes) and a severely hyperprolifer-
ative epidermis, sometimes with parakeratosis. From the
above data, it is therefore conceivable that the phenotype of
the InvEE mice could at least be partially dependent on an
increased production of IL-1a by the transgene positive,
suprabasal keratinocytes.
Given that the InvEE mice develop papillomas, it is in-
teresting that IL-1a may be involved in the generation of
epithelial neoplasia. IL-1a expression is potently induced in
the epidermis of mice treated with the tumor promoter TPA
(Lee et al, 1993, 1994a, b). IL-1a expression is increased in
a number of keratinocyte tumor cell lines and may also
promote cell survival and proliferation in squamous cell
carcinomas (La et al, 1999; Wolf et al, 2001). When mice
overexpressing IL-1a under the control of the K14 promoter
are subjected to two-stage chemical carcinogenesis with
DMBA and TPA, they are resistant to formation of pap-
illomas and squamous cell carcinomas, yet in response to
DMBA alone they develop carcinomas without the prior
appearance of papillomas (Murphy et al, 2003).
There are, however, differences between the InvEE and
the K14-IL-1a transgenic mice which suggest that IL-1 is
not the only factor regulated by MEK1. In particular, K14-IL-
1a mice have focal, rather than widespread, inflammatory
lesions and do not develop spontaneous papillomas
(Groves et al, 1995). In studies of cultured Invb1 keratin-
ocytes, we found that suprabasal integrin expression leads
to Erk activation and increased IL-1a expression by potent-
iating activation of the EGFR (Hobbs and Watt, 2003). InvEE
mice share many features with transgenic mice that over-
Figure 9
InvEE transgenic mice develop pap-
illomas. (A, B) H&E-stained sections of
different regions of one InvEE papilloma.
Note the hyperplastic hair follicles (aster-
isks) in (B). (C) section of InvEE papilloma
stained for Ki67. (D–H) Serial sections
from a spontaneous InvEE papilloma (D–
F) and a chemically induced papilloma
from a transgene-negative mouse (FVB
background). (G, H) were stained for in-
volucrin (D, G) and for total MEK1 (E, F, H).
The MEK1 antibody was pre-incubated
with blocking peptide as a control in (F). (I)
Section of InvEE papilloma stained for IL-
1a (I). Scale bars¼100 mm (A–F), (G, H)
and 200 mm (I).
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express an EGFR ligand, TGFa, from the keratin 14 pro-
moter (K14-TGFa mice), including generation of wound-in-
duced papillomas and the development of hyperprolifera-
tive but not parakeratotic epidermis (Vassar and Fuchs,
1991). While juvenile K14-TGFa mice develop no inflamma-
tory infiltrate, expression of another EGFR ligand, amp-
hiregulin, from the keratin 14 promoter in transgenic mice
(K14-AR mice) generates a phenotype with both epidermal
hyperproliferation and a cutaneous T-lymphocyte infiltrate
(Cook et al, 1997). Upregulation of EGFR ligands such as
amphiregulin and HB-EGF is Erk1/2 dependent (Ellis et al,
2001; Stoll et al, 2002) and the Erk MAPK pathway can
induce shedding of membrane bound pro-forms of EGFR
ligands including HB-EGF (Gechtman et al, 1999; Umata
et al, 2001). These data identify the Erk MAPK pathway as a
key regulator of EGFR ligand expression and processing
and suggest that the activation of Erk1/2 in InvEE transgenic
mice may trigger an increase in expression of various EGFR
ligands.
It is interesting that expression of activated MEK1 in
suprabasal epidermal layers (InvEE mice) can generate
spontaneous papillomas in a similar way to expressing Ras
in the epidermis. Papillomas occur in mice expressing ac-
tivated Ras in the epidermis from suprabasal keratin pro-
moters (Bailleul et al, 1990; Greenhalgh et al, 1993) and Ras
transgenics develop hyperkeratotic lesions of the foot pad
epidermis (Bailleul et al, 1990). This suggests that the most
important downstream effector of Ras for papilloma devel-
opment is the MEK/MAPK pathway, a finding that is con-
sistent with studies of the role of Ras in regulating
keratinocyte proliferation and differentiation (Dajee et al,
2002; Tarutani et al, 2003).
To conclude, from analysis of the InvEE transgenic mice
we have confirmed a role for MEK1 activation in the gen-
eration of hyperproliferative and inflammatory skin lesions.
The mechanism involves an increase in IL-1a production,
although it is likely that upregulation of other secreted fac-
tors, in particular EGFR ligands, is also important. This work
raises the interesting possibility that Erk MAPK inhibitors
could be used in the treatment of psoriasis, to reduce
epidermal hyperproliferation and prevent differentiation
defects (Haase et al, 2001) and also to downregulate
associated cutaneous inflammation. The existence of po-
tent small molecule inhibitors of MEK1 (Alessi et al, 1995;
Favata et al, 1998) would support the suitability of Erk as a
therapeutic target. Nevertheless, there may be a narrow
therapeutic window for the use of Erk inhibitors: sufficient
inhibitor must be applied to block excessive keratinocyte
proliferation and cytokine production yet too much would
deplete the stem cell compartment (Zhu et al, 1999; Dajee
et al, 2002) thereby compromising normal epidermal main-
tenance.
Materials and Methods
Generation of transgenic mice All animal studies were carried
out according to the terms of a UK Government Home Office li-
cence. To drive expression of an activated MEK1 construct in the
suprabasal layers of transgenic mouse epidermis, the involucrin
promoter (Carroll et al, 1993) was coupled to MEK1 containing two
activating point mutations (S217E/S221E; Alessi et al, 1994; Cowl-
ey et al, 1994). The involucrin promoter was excised from the
3700INV-pL2 plasmid (Carroll et al, 1993) using NotI to remove
the b-galactosidase insert and blunted using Klenow fragment
and dNTPs. The activated MEK1 construct was digested from
pBabepuroMEK1 (Zhu et al, 1999) with BamHI/SalI and also blunt-
ed. Ligation of MEK1 with the involucrin promoter plasmid was
performed using T4 DNA ligase. Vector sequences were removed
by SalI digestion and the resulting linearized construct was used
for pronucleus injection.
The involucrin–MEK1 construct (InvEE) was injected into the
male pronucleus of fertilized F1 hybrid (CBA  C57BL/6) mouse
embryos and implanted into pseudopregnant foster mothers. Mice
were screened by Southern blotting for the presence of the trans-
gene using a 1 kb fragment of the involucrin promoter construct
generated by XhoI digestion of 3700INV-pL2, essentially as de-
scribed previously (Carroll et al, 1995). Several positive mice were
identified and three were used to generate the founder lines for
subsequent experiments (founder lines 3359D, 3062A, and 3376A,
with low, medium, and high relative copy numbers of the transgene
respectively). Founder mice were paired with wild-type F1
(CBA  C57BL/6) mice and the offspring was subsequently
screened by PCR for transmission of the transgene. Mice were
typically maintained heterozygous for the transgene and were used
for analysis from 2–6 mo of age. In some experiments, InvEE mice
were crossed with transgenic mice in which the type 1 IL-1R is
expressed in the basal epidermal layer under the control of the
keratin 14 promoter in an FVB background (K14-IL-1R1; Groves
et al, 1996). In order to detect S-phase cells, mice were injected
i.p. with 300 mL of a 10 mg per mL BrdU (Sigma-Aldrich,
Gillingham, UK) stock 1 h before euthanization.
For genotyping, DNA was isolated from mouse tail snips and
either subjected to Southern blotting, as described above, or to PCR.
The following PCR primers were used. InvEE forward primer was:
50-TACGGAAGTGTTACTTCTGCTCTAAAAGCTG-30 (within SV40
intronic sequence); reverse: 50-ACTGGGCTTGTGGGAGACCTTG-
AAC-30 (within 50 region of MEK1). K14-IL-1R1 forward primer was:
50-CACGATACACCTGACTAGCTGGGTG-30 (within keratin 14 pro-
moter); reverse: 50-CATCACCCACAGGCTAGCGCCAACT-30 (within
keratin 14 promoter).
Preparation and immunostaining of tissues Skin samples were
usually collected from the back and/or belly of the mice. Skin from
InvEE positive mice was compared to sex- and body site-matched
negative littermate controls whenever possible. Skin was fixed
overnight in formol saline prior to paraffin embedding. Frozen sec-
tions were prepared from unfixed skin that had been placed in OCT
compound (BDH Poole, UK) and frozen in a bath of isopentane
cooled with liquid nitrogen. To prepare transverse sections through
the soles of feet, specimens were de-calcified for 10 d prior to
embedding in paraffin blocks. Whole mount preparations of tail
skin were prepared as described previously (Braun et al, 2003).
Prior to immunostaining, paraffin sections were dewaxed and
microwaved in Citra Plus antigen retrieval solution (BioGenex San
Ramon, California). Frozen sections were fixed in acetone at
201C for 10 min. If sections were to be labelled with antibodies to
horseradish peroxidase and then processed according to standard
immunohistochemistry techniques they were pre-treated with 3%
H2O2 in distilled H2O for 5 min to quench endogenous peroxidase
activity.
Sections were blocked in 10% goat serum (Sigma) in PBS for
1 h at room temperature. Antibodies were diluted in the blocking
solution. Antibody incubations were typically for 1 h at room tem-
perature. Sections were washed in PBS three times for 20 min per
wash. Sections were finally rinsed in dH2O and mounted in Gel-
vatol solution. Exceptions to this protocol were that incubation with
anti-phospho-Erk1/2, anti-mIL-1a, and anti-mIL-1b were carried
out at 41C overnight and that when using phospho-specific anti-
bodies PBS was replaced with TBS. In addition, BrdU was de-
tected as described previously (Niemann et al, 2002). In some
experiments, sections were double labelled using two primary
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antibodies of different species simultaneously followed by simul-
taneous incubation with two secondary antibodies coupled to dif-
ferent fluorophores. TOPRO and DAPI (Molecular Probes, Eugene,
Oregon) were used as nuclear counter-stains.
The following primary antibodies were used: mouse monoclon-
als anti-BrdU (BD Biosciences, San Jose, California), anti-mIL1-a
(DIACLONE Research, Besanc¸on, France) and anti-mIL1-b
(ab8320; Abcam, Cambridge, UK); rabbit anti-Ki67 (Vector Labo-
ratories, Peterborough, UK), rabbit anti-cornifin (kind gift of Anton
Jetten; Fujimoto et al, 1997), rabbit anti-mouse involucrin (Li et al,
2000), rabbit antibodies to keratin 6, keratin 10, keratin 14, loricrin,
and filaggrin (Covance, Princeton, New Jersey); rabbit anti-keratin
17 (generous gift from Pierre Coulombe; McGowan and Coulombe,
1998); rabbit anti-phospho Erk1/2 (Thr202/Tyr204; Cell Signaling
Technology, Beverly, Massachusetts); rabbit anti-MEK1 (SC-219;
Santa Cruz, Santa Cruz, California). In addition, the following rat
monoclonal antibodies to immune cells were used: CD3, CD4,
CD8a (all from BD Biosciences), F4/80 antigen, mouse neutrophil
antigen (Serotec, Sidlington, UK), and DEC-205 (kind gift of Cae-
tano Reis e Sousa; Kraal et al, 1986). Secondary antibodies were
either coupled to Alexa 488 or Alexa 594 and purchased from
Molecular Probes or coupled to horseradish peroxidase (HRP) and
obtained from BD Biosciences or Sigma.
RT-PCR Total RNA was extracted from the back skin of adult mice
using Trizol Reagent (Gibco-BRL Gaithersburg, Maryland) accord-
ing to the manufacturer’s instructions. RNA from two transgenic
and two negative littermates was examined. First-strand cDNA
synthesis was performed using the Superscript SSIII reverse tran-
scriptase kit (Gibco-BRL) with a T7-polyT primer. Second-strand
cDNA synthesis and semi-quantitative PCR were carried out using
ExTaq (Takara Cambrex Bio Science, Wokingham, UK). The IL1-a
primers were: GTTCTGCCATTGACCATCTCTCT (forward) and CA-
AGTGGTGCTGAGATAGTGTTTGT (reverse). The IL-1b primers (Ta-
kacs and Kauma, 1996) were ATGGCAACTGTTCCTGAACTCAACT
(forward) and CAGGACAGGTATAGATTCTTTCCTTT (reverse). The
mouse GAPDH primers were TGATGACATCAAGAAGGTGAAG
(forward) and TCCTTGGAGGCCATGTAGGCCAT (reverse). PCR
was performed with cycles at 941C for 30 s, 601C for 30 s and 721C
for 2 min, with a final step after the last cycle at 721C for 3 min.
PCR products were collected every 5 cycles from 15 to 35 and
examined by electrophoresis on 2% agarose gels.
Cell culture Primary mouse keratinocytes were isolated from
neonatal mice as described previously (Roper et al, 2001). Cells
from one mouse were plated into one 35 mm diameter collagen-
coated petri dish (BD Biosciences). The cells were cultured at 321C
in complete low calcium FAD medium. The composition of stand-
ard (‘‘high-calcium’’) FAD medium was 1 part Ham’s F12 medium
plus 3 parts Dulbecco’s Modified Eagle’s medium (DMEM), sup-
plemented with 1.8  104 M adenine, 10% FCS, 1010 M cholera
toxin, 0.5 mg per mL hydrocortisone, 5 mg per mL insulin and 10 ng
per mL EGF (Haase et al, 2001). To prepare low-calcium medium,
the F12 and DMEM formulations were calcium free and the FCS
was depleted of divalent cations by treatment with Chelex deion-
izing resin (BioRad, Hemel, Hempstead, UK) (Roper et al, 2001);
this medium was supplemented with 1% standard complete FAD
medium to bring the final concentration of calcium ions to ap-
proximately 0.1 mM. Keratinocytes were passaged at 1:2 when
they reached confluence. To induce stratification, keratinocytes
were transferred from low calcium to standard complete FAD me-
dium overnight.
Immunoblotting The following antibodies were used for western
blotting. Rabbit anti-phospho-Erk1/2 (Thr202/Tyr204) was pur-
chased from Cell Signaling Technology. Mouse monoclonal anti-
Erk2 (SC-1647) and rabbit anti-MEK1 (SC-219) were purchased
from Santa Cruz. Goat anti-mouse IL-1a and goat anti-mouse IL-
1ra were purchased from R&D Systems (Abingdon, UK). A mouse
monoclonal antibody to the (His)6 tag was obtained from Abcam
and a mouse monoclonal to actin (clone AC40) was purchased
from Sigma.
Keratinocytes were washed twice in PBS and lysed on ice in a
modified RIPA buffer containing 50 mM Tris pH 8.0, 150 mM NaCl,
1% NP-40, 0.1% SDS, 0.5% deoxycholate, 5 mM EDTA, 1% Triton
X-100 with protease and phosphatase inhibitor cocktails (Sigma).
Lysates were stored at –201C. Immediately prior to use, lysates
were thawed and centrifuged at 2,000 g for 10 min at 41C on a
benchtop centrifuge. The pellet was discarded and the supernat-
ant was assayed for protein content before being loaded onto a
polyacrylamide gel.
Proteins were subjected to electrophoresis on either 12% or
14% polyacrylamide gels using the Laemmli buffer system and
transferred to PVDF membrane (Millipore, Watford, UK) as de-
scribed previously (Hobbs and Watt, 2003). Membranes were
blocked in 5% milk powder (99% fat free; Premier Brands,
Spalding, UK) dissolved in 0.1% Tween-20 and TBS (TBST). Pri-
mary antibodies were diluted in the blocking solution or in 5% BSA
in TBST. Incubation with primary antibody was at 41C overnight
with gentle agitation. After three washes in TBST, each for 20–30
min, the blots were incubated for 1 h at room temperature with
HRP-conjugated species-specific secondary antibodies (BD Bio-
sciences or Sigma), washed again in TBST and then visualized
using a chemiluminescence kit (Western Lightning; NEN Perkin
Elmer, Beaconsfield, UK) according to the manufacturer’s instruc-
tions.
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